Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City

Rhea-AI Summary

Co-Diagnostics (NASDAQ: CODX) said its joint venture CoMira Diagnostics secured an industrial land allocation in Sudair Industrial City, Saudi Arabia, approved by MODON on April 2, 2026. The site is intended for a molecular diagnostics manufacturing facility; final lease hinges on site infrastructure completion.

The facility aims to localize production of molecular instruments and assays, support Saudi Vision 2030 objectives, and position CoMira among early domestic diagnostic manufacturers; the Co-Dx PCR platform remains subject to regulatory review.

News Market Reaction – CODX

-4.94%

3 alerts

-4.94% Session close to close

-13.6% Trough Tracked

$5.55M Market Cap

0.0x Rel. Volume

In the Apr 2 session, CODX declined 4.94%, reflecting a moderate negative market reaction. Argus tracked a trough of -13.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights CoMira’s progress toward a manufacturing facility in Sudair Industrial ...

Analysis

This announcement highlights CoMira’s progress toward a manufacturing facility in Sudair Industrial City, supporting localization of Co-Dx PCR technologies in Saudi Arabia and broader Middle East and North Africa markets. It follows earlier JV milestones for CoSara in India, reinforcing Co-Diagnostics’ partnership-led expansion model. Investors may watch for execution on construction, regulatory clearances for the Co-Dx PCR platform, and how these facilities translate into revenue, especially given recently reported losses and going-concern disclosures.

Previous Partnership Reports

3 past events · Latest: Feb 05 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 05	JV regulatory license	Positive	+0.0%	CoSara secured CDSCO license to manufacture PCR Pro instrument for India.
Dec 18	JV conference invite	Positive	+5.3%	CoSara invited to advanced TB diagnostics course with global health partners.
Nov 05	Strategic alternatives JV	Positive	+3.5%	Maxim Group engaged to explore SPAC or similar listing for CoSara JV.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Partnership and JV announcements have historically seen modestly positive or flat next-day moves for CODX, contrasting with the current negative price action.

Recent Company History

Over recent months, Co-Diagnostics has repeatedly highlighted partnerships and joint ventures to expand its PCR technology. Prior JV news for CoSara included securing a CDSCO license to manufacture the PCR Pro instrument in India, participation in an advanced TB diagnostics course, and engagement of Maxim Group to pursue a potential SPAC or similar U.S.-listed transaction. Those partnership items saw next-day moves between 0% and about 5%. Today’s CoMira facility approval in Saudi Arabia continues this strategy of leveraging regional partners for manufacturing and commercialization.

Key Terms

molecular diagnostic testing solutions, molecular diagnostic tests, pcr platform, assays, +3 more

7 terms

molecular diagnostic testing solutions medical

"position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions"

Molecular diagnostic testing solutions are tools and services that identify specific genetic material or biological markers in blood, saliva, or tissue to detect diseases, infections, or treatment targets—think of them as a highly sensitive detective kit that reads molecular fingerprints. Investors care because these solutions drive recurring revenue from tests and consumables, depend on regulatory approvals and reimbursement, and can scale rapidly if they offer faster, cheaper, or more accurate results than alternatives.

molecular diagnostic tests medical

"a unique, patented platform for the development of molecular diagnostic tests"

Molecular diagnostic tests analyze a patient’s biological sample to detect specific molecules—such as DNA, RNA, or proteins—that signal an infection, genetic condition, or disease state. For investors, they matter because they underpin demand for laboratory equipment, reagents and testing services, can affect revenue predictability and reimbursement decisions, and often determine how quickly new treatments are adopted—think of them as the forensic tools that guide medical decisions.

pcr platform medical

"including the Co-Dx PCR platform*, and is expected to support our international expansion"

A PCR platform is a laboratory system—hardware, reagents and software—used to find and copy tiny amounts of genetic material so they can be detected and measured, like a photocopier that makes a whisper loud enough to hear. Investors care because these platforms drive sales, recurring consumable revenue, regulatory approvals and customer lock‑in in diagnostics and drug development, so adoption and performance directly affect a company’s growth and risk profile.

assays medical

"facility dedicated to molecular diagnostic instruments and assays, which would be designed"

Assays are laboratory tests that detect or measure a specific substance, molecule, or biological activity—for example whether a drug reaches its target, how much of a chemical is present, or whether a diagnostic marker exists. Think of them like quality-control checks or sensors that tell you if an ingredient and its amount meet a standard. For investors, assay results drive clinical decisions, regulatory approval, manufacturing quality and timelines, all of which affect a company’s value and risk.

regulatory requirements regulatory

"designed and built to meet CoMira's specific production and regulatory requirements."

Regulatory requirements are the rules and standards set by government agencies that businesses must follow to operate, report financials, protect consumers, or meet safety and environmental standards. For investors they matter because meeting or missing these rules can affect a company’s costs, reputation and legal standing—like a car that must pass inspection: compliance keeps it running and saleable, while violations can cause fines, delays or lost value.

fda regulatory

"subject to review by the FDA and/or other regulatory bodies and is not yet available"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

supply chain resilience technical

"while strengthening regional manufacturing capabilities and supply chain resilience."

Supply chain resilience is the ability of a system to quickly adapt and recover from disruptions that could interrupt the flow of goods, services, or resources. It is like having a backup plan or extra flexibility to keep things running smoothly despite unexpected problems. For investors, strong supply chain resilience can indicate a company's or economy's capacity to maintain stability and continue growth even during challenging times.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi Arabia

SALT LAKE CITY, April 2, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoMira Diagnostics ("CoMira"), the Company's joint venture ("JV") with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia ("KSA"), has secured an industrial land allocation in Sudair Industrial City located in the Riyadh region, one of Saudi Arabia's leading industrial hubs, following approval by the Saudi Authority for Industrial Cities and Technology Zones ("MODON"). The final lease agreement is expected to be executed upon completion of site infrastructure requirements.

Sudair Industrial City, developed and managed by MODON, plays a central role in the KSA's Vision 2030 strategy to diversify the economy and strengthen local manufacturing capabilities.

"We believe that a manufacturing facility in Sudair Industrial City could play an important role in achieving our JV's mission to localize advanced diagnostic technologies within the KSA, including the Co-Dx PCR platform*, and is expected to support our international expansion objectives across the Middle East and Northern Africa," remarked Dwight Egan, CEO of Co-Diagnostics.

The allocated site is intended to support, subject to further development activities and approvals, the development of a state-of-the-art manufacturing facility dedicated to molecular diagnostic instruments and assays, which would be designed and built to meet CoMira's specific production and regulatory requirements.

The project aligns with Saudi Arabia's increasing emphasis on local content and domestic production, particularly in government procurement programs where in-country manufacturing may be a key differentiator.

Ihssan Rjoob, CEO of CoMira Diagnostics, commented, "Securing our presence in Sudair Industrial City represents a foundational milestone for CoMira. This step reflects our long-term commitment to localizing advanced molecular diagnostics in Saudi Arabia, contributing to the Kingdom's Vision 2030 objectives, and advancing CoMira's mission to establish a fully integrated molecular diagnostics platform in Saudi Arabia."

Mr. Rjoob continued, "Once operational, the facility is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions, enabling faster access to innovative diagnostics while supporting national healthcare resilience.

"Through this facility, we intend to bring high-quality, scalable diagnostic solutions closer to patients while strengthening regional manufacturing capabilities and supply chain resilience."

*The Co-Dx PCR platform (including the PCR Home^®, PCR Pro^®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding: (i) the anticipated execution of a final lease agreement for the allocated land in Sudair Industrial City; (ii) the planned development, timing, scope, and operationalization of a manufacturing facility by CoMira Diagnostics; (iii) the ability of such facility to support manufacturing of molecular diagnostic instruments and assays; (iv) expectations regarding CoMira's positioning as an early domestic manufacturer within the Kingdom of Saudi Arabia; (v) the potential benefits of local manufacturing, including participation in government procurement programs and contribution to Saudi Arabia's Vision 2030 objectives; and (vi) the Company's broader international expansion strategy across the Middle East and North Africa. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management as of the date of this release. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that a definitive lease agreement is not executed on anticipated terms or timelines, or at all; risks associated with satisfying infrastructure requirements and other conditions precedent; risks related to the design, financing, construction, and timely completion of the contemplated manufacturing facility; risks associated with operating through a joint venture, including governance, funding, and partner-related risks; risks related to obtaining and maintaining required regulatory approvals in the Kingdom of Saudi Arabia and other jurisdictions; risks that anticipated benefits of localization and participation in government procurement programs are not realized; uncertainties associated with market acceptance and adoption of the Company's products; competitive dynamics in the global molecular diagnostics market; execution risks associated with international expansion; and general economic, geopolitical, and public health conditions in the regions in which the Company operates or intends to operate. Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-receives-approval-for-manufacturing-facility-in-kingdom-of-saudi-arabias-sudair-industrial-city-302732479.html

SOURCE Co-Diagnostics

FAQ

What did Co-Diagnostics (CODX) announce about CoMira on April 2, 2026?

Co-Diagnostics announced CoMira secured an industrial land allocation in Sudair Industrial City, approved by MODON. According to the company, the allocation is intended for a molecular diagnostics manufacturing facility with a final lease pending site infrastructure completion.

How will the Sudair site affect CoMira's manufacturing plans for CODX products?

The Sudair site is intended to host a state-of-the-art facility for instruments and assays. According to the company, it would support localization of Co-Dx PCR platform production and regional supply chain resilience once developed and approved.

Is the Co-Dx PCR platform available for sale in Saudi Arabia after the CoMira land allocation?

No, the Co-Dx PCR platform remains subject to regulatory review and is not yet available for sale. According to the company, regulatory approvals are required before commercial availability in Saudi Arabia and other markets.

What approvals are required before CoMira can operate the Sudair manufacturing facility for CODX?

The final lease and facility development require completion of site infrastructure and further approvals. According to the company, MODON approved the land allocation but additional development and regulatory clearances remain necessary.

How does CoMira's Sudair allocation relate to Saudi Vision 2030 and CODX's regional strategy?

The Sudair allocation aligns with Vision 2030 goals to boost local manufacturing and content. According to the company, the facility is expected to support international expansion across the Middle East and North Africa and strengthen domestic capabilities.